Författare: johan@emergers.se

NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects

Analys, Research

With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments corresponding to 27.1%, Nanexa is...

Read More

KEBNI: Mixed bag in Q3 – steep growth ahead

Analys, Research

Despite 29% top-line growth in Q3’23, sales were a bit soft due to a slower-than-anticipated ramp-up of deliveries to Saab. This has led...

Read More

KEBNI: Site visit provided clarity on scale-up and insight into ScaffSense venture

Analys, Research

Our site visit to KebNi’s new production facility in Karlskoga not only showed production up and running, but also how it can scale...

Read More

NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal

Analys, Research

With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa now has...

Read More

NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025

Analys, Research

As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount and amount. This will...

Read More

QLUCORE: Streamlining focus to extend financial runway

Analys, Research

In Q1’23/24, both sales of Qlucore Omics Explorer and costs were slightly higher than we expected. To extend its runway, Qlucore will...

Read More

GRANGEX: Steep acceleration towards two permitted CO2-free iron ore projects

Analys, Research

GRÄNGESBERG EXPLORATION 2023 has proven a pivotal year for GRANGEX. Soon after the environmental court’s approval to restart...

Read More

KEBNI: Soft Q2 ahead of ramp-up in H2’23-2026

Analys, Research

Sales in Q2’23 of SEK 7.4m were softer than we expected. While we are optimistic about a significant increase in sales in H2’23...

Read More

NANEXA: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest

Analys, Research

Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum. NEX-20 is set to provide a more...

Read More

KEBNI: Financing and second volume order clear path for sales surge in 2023-2026

Analys, Research

Late Wednesday evening KebNi announced that it has raised SEK 29.6m from a group of professional investors, including the two largest of...

Read More

For new research on growth stocks, sign up to our newsletter